A good glycemic response was seen following the addition of GLP-1 RA therapy with HbA1C reductions ranging from 0.40 to 0.94% regardless of baseline insulin dosage, baseline BMI, or duration of diabetes. The gene discussed is GCG; the disease is diabetes mellitus.